Biocon Limited — Updates, 07-03-2025: Press Release

Biocon Biologics has announced positive results from a pivotal Phase 3 study of its biosimilar Yesintek™, targeting Ustekinumab for the treatment of chronic plaque psoriasis. The trial demonstrated that Yesintek™ was equivalent in efficacy, safety, immunogenicity, and pharmacokinetics to the reference product Stelara, which is significant for enhancing patient access to therapeutic alternatives. The primary endpoint, assessed via the Psoriasis Area and Severity Index (PASI) score at week 12, showed a mean difference of just 0.68%, well within acceptable margins. Additionally, Yesintek™ maintained a similar safety profile throughout the duration of the study, reinforcing its role as a viable competitor in the biosimilar market. With this positive data set, Biocon Biologics strengthens its commitment to providing affordable biosimilar therapies globally, particularly as it expands its portfolio addressing autoimmune diseases. Investors should view this as a strong opportunity for potential growth given the increasing demand for cost-effective treatment options.